Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

The brand on Tuesday is announcing its expansion into all Walmart doors, following its latest launch: Multi-Symptom, a ...

We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novo ...

Zepbound, Lilly’s obesity drug, has overtaken Novo’s equivalent, Wegovy, in the US and now commands over 50 per cent of the ...

Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 20 cents in first-quarter 2025 compared with the ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on more ...

As weight loss medications, including Ozempic and WeGovy, have gained popularity across the U.S., they are not without side effects, some serious. According to a May 2024 CNN report, as many as 1 in 8 ...